Dr. Kurkul is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2600 Scripture St
Denton, TX 76201Phone+1 940-382-1022Fax+1 972-234-0819
Summary
- I am a Hematologist Oncologist, certified and specializing in high quality academic medicine within a community-based environment. My primary focus is on outpatient care where I treat a diverse range of benign hematology cases and prevalent malignancies. I am privileged to operate within an exceptional referral network in the DFW metroplex, facilitated by Texas Oncology and our affiliated Sarah Cannon Cancer Center. This network grants me access to advanced medical technology and innovative treatment methodologies.
In addition to this, I hold the position of Principal Investigator on numerous clinical trials, the majority of which are industry-funded. In my spare time, I have the honor of chairing the Hematology/Oncology rotation for medical residents at HCA Denton. I also take pleasure in teaching and mentoring residents at the local THR program. I am consistently open to engaging in discussions regarding potential reforms in the curriculum.
Education & Training
- UMass Chan Medical SchoolFellowship, Hematology and Medical Oncology, 2014 - 2017
- Stony Brook Medicine/University HospitalResidency, Internal Medicine, 2011 - 2014
- University of Massachusetts Medical SchoolClass of 2011
Certifications & Licensure
- MA State Medical License 2016 - 2025
- TX State Medical License 2018 - 2025
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL) Start of enrollment: 2012 Oct 31
- A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer Start of enrollment: 2021 Oct 04
- Breast Cancer Index (BCI) Registry Start of enrollment: 2021 Apr 14
- Join now to see all
Press Mentions
- State-of-the-art screening, treatments make breast cancer more treatable than everOctober 11th, 2021
Committees
- Ethics Chair, THR Medical Executive Committee 2020 - Present
- Clinical Hematologist, THR Hematology Committee 2018 - Present
Professional Memberships
- Member
- Member
- Member
External Links
- Texas Oncology Profilehttps://www.texasoncology.com/doctors/charles-kurkul
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: